Skip to main content

Genome Therapeutics Changes Name to Oscient

NEW YORK, April 13 (GenomeWeb News) - Genome Therapeutics said today that it has changed its name to Oscient Pharmaceuticals "to better reflect its focus on drug development and commercialization" following its merger with Genesoft Pharmaceuticals in February.

Genome Therapeutics shareholders approved the change to Oscient (pronounced AWE-see-ent) today at the company's annual meeting in Boston. The name change will take effect immediately and the company's stock will continue to trade on Nasdaq under the ticker symbol "GENE."

Oscient's corporate headquarters will remain in Waltham, Mass., with west coast offices in South San Francisco.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.